Acta Med. 2008, 51: 19-24

https://doi.org/10.14712/18059694.2017.3

Off-label Utilization of Antidepressants

Daniele Fabio Zullinoa, Bruno Schwartzb, Romain Bilancionic, Pierre Baumannc

aUniversity Hospitals of Geneva, Division of Substance Abuse, Geneva, Switzerland
bPrivate Practice, Geneva, Switzerland
cUniversity Department of Psychiatry, Prilly-Lausanne, Switzerland

Received March 1, 2007
Accepted March 1, 2008

References

1. Ambühl B, Würmle O, Michel G. Die Verschreibungspraxis von Psychopharmaka in einer psychiatrischen Unversitätsklinik. Psychiatr. Prax. 1993; 20:70–73.
2. Bingefors K, Isacson D, von Knorring L. Antidepressant dose patterns in Swedish clinical practice. International Clinical Psychopharmacology 1997; 12: 283–290. <https://doi.org/10.1097/00004850-199709000-00005>
3. Boerner RJ, Müller HJ. The importance of newer antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry 1999; 32:119–126. <https://doi.org/10.1055/s-2007-979217>
4. Bouhassira M, Allicar MP, Blachier C, Nouveau A, Rouillon F. Which patients receive antidepressants? A ‘real world’ telephone study. Journal of Affective Disorders 1998; 49:19–26. <https://doi.org/10.1016/S0165-0327(97)00193-6>
5. Egberts ACG, Veenstra M, de Jong-van den Berg LTW. Antidepressant drug choice for first users in two regions in the Netherlands. Pharm. World Sci. 1999; 21:132–136. <https://doi.org/10.1023/A:1008675402004>
6. Grohmann R, Rüther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32:21–28. <https://doi.org/10.1055/s-2007-979184>
7. Laux G, Baier D. Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Pharmacopsychiatry 1997; 30(suppl):21–27. <https://doi.org/10.1055/s-2007-979513>
8. Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. Journal of Clinical Psychopharmacology 1999; 19:132–140. <https://doi.org/10.1097/00004714-199904000-00007>
9. Lippert E, Aigner JM, Grohmann R, Klein HE, Schmauss M, Rüther E. Anwendungshäufigkeiten und Dosierungen von Psychopharmaka an psychiatrischen Versorgungskrankenhäusern – Ergebnisse aus dem Arzneimittelüberwachungsprojekt Bayern. Psychopharmakotherapie 1996; 3:178–183.
10. Mayer LES, Walsh BT. The use of selective serotonin reuptake inhibitors in eating disorders. Journal of Clinical Psychiatry 1998; 59(suppl 15):28–34.
11. Morgan R, Gopalaswamy AK. Psychotropic drugs: another survey of prescribing patterns. Br.J.Psychiatry 1984; 144:298–302. <https://doi.org/10.1192/bjp.144.3.298>
12. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br.J.Psychiatry 1987; 150:501–504. <https://doi.org/10.1192/bjp.150.4.501>
13. Olfson M, Pincus HA, Dial TH. Professional practice patterns of U.S. psychiatrists. American Journal of Psychiatry 1994; 151:89–95.
14. Ornstein S, Stuart G, Jenkins R. Depression diagnoses and antidepressant use in primary care practices: a study from the Practice Partner Research Network (PPRNet). J Fam.Pract. 2000; 49:68–72.
15. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, et al. Prescribing trend in psychotropic medications: primary care, psychiatry, and other medical specialities. JFMA 1998; 279:526–531. <https://doi.org/10.1001/jama.279.7.526>
16. Pomerantz JM, Finkelstein SN, Berndt ER, Poret AW, Walker LE, Alber RC, et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin.Psychiatry 2004; 65: 395–404. <https://doi.org/10.4088/JCP.v65n0316>
17. Rittmansberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur.Psychiatry 1999; 14:33–40. <https://doi.org/10.1016/S0924-9338(99)80713-5>
18. Tinsley JA, Shadid GE, Li H, Offord KP, Agerter DC. Psychotropic prescribing practices and educational needs: a survey of family physicians and psychiatrists. Gen.Hosp.Psychiat. 1998; 20:360–367. <https://doi.org/10.1016/S0163-8343(98)00049-8>
19. Tylee A. Depression in the community: physician and patient perspective. Journal of Clinical Psychiatry 1999; 60(suppl 7):12–16.
20. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001; 34: 1–9. <https://doi.org/10.1055/s-2001-15873>
21. Zullino D, Baumann P, Grohmann R, Greil W. L’importance de la pharmacovigilance en psychiatrie – Le Projet AMSP (Arzneimittelsicherheit in der Psychiatrie). Revue médicale de la Suisse Romande 2000; 120:105–109.
22. Zullino D, Bondolfi G, Baumann P. The serotonin paradox: negative symptoms and SSRI augmentation. Int. J. Psych. Clin. Prac. 1998; 2:19–26. <https://doi.org/10.3109/13651509809115109>
23. Zullino DF, Horvath A, Greil W, Grohmann R, Hippius H, Eich P, et al. Die Bedeutung der Pharmakovigilanz in der Psychiatrie: das AMSP-Projekt (Arzneimittelsicherheit in der Psychiatrie). Schw. Arch. Neurol. Psychiatr. 2002; 153:266–271.
24. Zullino D, Mayland G, Schmidt LG, Fahndrich E, Greil W, Horvath A, et al. Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences. Int J Clin Pharmacol Ther 2005; 43: 339–49. <https://doi.org/10.5414/CPP43339>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive